Apolipoprotein E region molecular signatures of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Summary: Although the APOE region is the strongest genetic risk factor for Alzheimer's diseases (AD s), its pathogenic role remains poorly understood. Elucidating genetic predisposition to AD s, a subset of age‐related diseases characteristic for postreproductive period, is hampered by the undefined role of evolution in establishing molecular mechanisms of such diseases. This uncertainty is inevitable source of natural‐selection–free genetic heterogeneity in predisposition to AD s. We performed first large‐scale analysis of linkage disequilibrium (LD) structures characterized by 30 polymorphisms from five genes in the APOE 19q13.3 region (BCAM, NECTIN 2, TOMM 40, APOE, and APOC 1) in 2,673 AD‐affected and 16,246 unaffected individuals from five cohorts. Consistent with the undefined role of evolution in age‐related diseases, we found that these structures, being highly heterogeneous, are significantly different in subjects with and without AD s. The pattern of the difference represents molecular signature of AD comprised of single nucleotide polymorphisms (SNP s) from all five genes in the APOE region. Significant differences in LD in subjects with and without AD s indicate SNP s from different genes likely involved in AD pathogenesis. Significant and highly heterogeneous molecular signatures of AD s provide unprecedented insight into complex polygenetic predisposition to AD s in the APOE region. These findings are more consistent with a complex haplotype than with a single genetic variant origin of AD s in this region.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Broken Limits to Life Expectancy
Oeppen, J., & Vaupel, J. W. (2002) · Science · doi:10.1126/science.1069675 · Cited by 2,819
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“Significance of the r2 estimates was characterized using chisquare statistics, defined as v2 = r2N, where N = 2n is the number of gametes and n is the sample size (Lewontin, 1988).”
MethodWard, L. D., & Kellis, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr917 · Cited by 2,229
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 2×
“…identified a number of mutations in the APP gene (chromosome 21) and two homologous genes, PSEN1 (chromosome 14) and PSEN2 (chromosome 1), that appear to be causative in the early (familial) form of AD (Goate et al., 1991; Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995).”
BackgroundAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Astrocyte barriers to neurotoxic inflammation
Sofroniew, M. V. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3898 · Cited by 1,202 · cited 1×
“Recent data indicate that the function of astrocytes can change from potent pro-inflammatory to potent anti-inflammatory in response to regulatory signals (Sofroniew, 2015).”
BackgroundThe Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
On measures of gametic disequilibrium.
Lewontin, R. C. (1988) · Genetics · doi:10.1093/genetics/120.3.849 · Cited by 712
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides
Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1058 · Cited by 571 · cited 1×
“To contrast LD between the AD-affected and unaffected groups, we used a permutation procedure by shuffling the case and noncase labels (Krzanowski, 1993) to obtain an empirical distribution of Z2 under the null hypothesis r1 = r0, from which a p-value was computed.”
MethodMicrobes and Alzheimer’s Disease
Itzhaki, R. F., Lathe, R., Balin, B. J., Ball, M. J., Bearer, E. L., Braak, H., Bullido, M. J., Carter, C., Clerici, M., Cosby, S. L., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160152 · Cited by 532
Inferences about Linkage Disequilibrium
Weir, B. S. (1979) · Biometrics · doi:10.2307/2529947 · Cited by 516 · cited 1×
“LD was characterized by the correlation coefficient r using haplotypebased (Weir, 1979) and genotype-based (Zaykin, Meng & Ehm, 2006) methods.”
MethodWard, A., Crean, S., Mercaldi, C. J., Collins, J. M., Boyd, D., Cook, M. N., & Arrighi, H. M. (2012) · Neuroepidemiology · doi:10.1159/000334607 · Cited by 349
Harris, S. A., & Harris, E. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142853 · Cited by 279
Comparative genomics of autism and schizophrenia
Crespi, B., Stead, P., & Elliot, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906080106 · Cited by 262
Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene
Artiga, M. J., Bullido, M. J., Sastre, I., Recuero, M., Garcı́a, M. A., Aldudo, J., Vázquez, J., & Valdivieso, F. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01543-3 · Cited by 229 · cited 1×
“Another study also reported that rs405509 regulates APOE promoter activity (Artiga et al., 1998).”
BackgroundGenetics of Longevity and Aging
Vijg, J., & Suh, Y. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104617 · Cited by 142 · cited 1×
“This problem is complicated by recent changes in human life expectancy (Oeppen & Vaupel, 2002) and the fitness landscape (Corella & Ordovas, 2014; Crespi, Stead & Elliot, 2010; Kulminski, 2013; Vijg & Suh, 2005).”
BackgroundGrehan, S., Tse, E., & Taylor, J. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-03-00812.2001 · Cited by 138
Aging and cardiovascular diseases: the role of gene-diet interactions
Corella, D., & Ordovás, J. M. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.08.002 · Cited by 83
Cited by
Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond
Fuior, E. V., & Gafencu, A. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235939 · Cited by 186
Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping
Belloy, M. E., Eger, S. J., Le Guen, Y., Damotte, V., Ahmad, S., Ikram, M. A., Ramirez, A., Tsolaki, A. C., Rossi, G., Jansen, I. E., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00962-4 · Cited by 22
Haplotype architecture of the Alzheimer's risk in the APOE region via co‐skewness
Kulminski, A. M., Philipp, I., Loika, Y., He, L., & Culminskaya, I. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12129 · Cited by 10
Self-citation
Metadata
- Authors
- Kulminski, A. M., Huang, J., Wang, J., He, L., Loika, Y., & Culminskaya, I.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2018-05-23
- Volume
- 17
- Issue
- 4
- Pages
- e12779-e12779
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W2804455730
- Cited by
- 45
- References
- 18
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.